NasdaqGS:CERTHealthcare Services
Certara (CERT): Evaluating Valuation After Profit Gains and New Biopharma Tech Launches
Certara (CERT) just posted higher profits and rising revenue for the latest quarter, catching investors’ attention. The company has also rolled out new software tools such as TFL Studio, further strengthening its offerings in biopharma technology.
See our latest analysis for Certara.
Certara’s strong earnings and new product launches have come amid a challenging backdrop, with the share price down 30% in the past month and 24% over the last quarter as sentiment cooled, even though operational...